| 000 | 01732 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518090251.0 | ||
| 264 | 0 | _c20210107 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1879-0712 | ||
| 024 | 7 |
_a10.1016/j.ejphar.2020.173040 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGanbaatar, Byambasuren | |
| 245 | 0 | 0 |
_aEmpagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. _h[electronic resource] |
| 260 |
_bEuropean journal of pharmacology _cMay 2020 |
||
| 300 |
_a173040 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdipose Tissue _xdrug effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAorta, Thoracic _xdrug effects |
| 650 | 0 | 4 |
_aBenzhydryl Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Experimental _xblood |
| 650 | 0 | 4 |
_aEicosanoids _xmetabolism |
| 650 | 0 | 4 |
_aEndothelium, Vascular _xdrug effects |
| 650 | 0 | 4 |
_aGlucosides _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Knockout, ApoE |
| 650 | 0 | 4 |
_aPlaque, Atherosclerotic _xetiology |
| 650 | 0 | 4 |
_aSodium-Glucose Transporter 2 Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aStreptozocin _xtoxicity |
| 700 | 1 | _aFukuda, Daiju | |
| 700 | 1 | _aShinohara, Masakazu | |
| 700 | 1 | _aYagi, Shusuke | |
| 700 | 1 | _aKusunose, Kenya | |
| 700 | 1 | _aYamada, Hirotsugu | |
| 700 | 1 | _aSoeki, Takeshi | |
| 700 | 1 | _aHirata, Ken-Ichi | |
| 700 | 1 | _aSata, Masataka | |
| 773 | 0 |
_tEuropean journal of pharmacology _gvol. 875 _gp. 173040 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejphar.2020.173040 _zAvailable from publisher's website |
| 999 |
_c30688448 _d30688448 |
||